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Abstract
Synaptic remodeling during early postnatal development lies behind neuronal networks refinement and nervous system 
maturation. In particular, the respiratory system is immature at birth and is subjected to significant postnatal development. 
In this context, the excitatory/inhibitory balance dramatically changes in the respiratory-related hypoglossal nucleus (HN) 
during the 3 perinatal weeks. Since, development abnormalities of hypoglossal motor neurons (HMNs) are associated with 
sudden infant death syndrome and obstructive sleep apnea, deciphering molecular partners behind synaptic remodeling in 
the HN is of basic and clinical relevance. Interestingly, a transient expression of the neuronal isoform of nitric oxide (NO) 
synthase (NOS) occurs in HMNs at neonatal stage that disappears before postnatal day 21 (P21). NO, in turn, is a determining 
factor for synaptic refinement in several physiopathological conditions. Here, intracerebroventricular chronic administration 
(P7–P21) of the broad spectrum NOS inhibitor l-NAME (N(ω)-nitro-l-arginine methyl ester) differentially affected excita-
tory and inhibitory rearrangement during this neonatal interval in the rat. Whilst l-NAME led to a reduction in the number 
of excitatory structures, inhibitory synaptic puncta were increased at P21 in comparison to administration of the inactive 
stereoisomer d-NAME. Finally, l-NAME decreased levels of the phosphorylated form of myosin light chain in the nucleus, 
which is known to regulate the actomyosin contraction apparatus. These outcomes indicate that physiologically synthesized 
NO modulates excitatory/inhibitory balance during early postnatal development by acting as an anti-synaptotrophic and/or 
synaptotoxic factor for inhibitory synapses, and as a synaptotrophin for excitatory ones. The mechanism of action could rely 
on the modulation of the actomyosin contraction apparatus.
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Introduction
Synaptic remodeling during neonatal development lies 
behind neuronal networks refinement and nervous system 
maturation. The adjustment and/or removal of existing syn-
apses and the generation of new synapses are the substratum 
for synaptic reorganization occurring in learning, memory 
formation, and refinement of sensorimotor functions (Benson 
et al. 2001; Sunico et al. 2005). At the neonatal stage, redun-
dant synaptic connections are transiently formed. Once the 
initial patterns of synaptic connections are settled down, 
there are a refinement and remodeling of these initial projec-
tions into highly tuned and functioning circuits (Goodman 
and Shatz 1993). During this developmental period, some 
synapses are strengthened whereas other redundant connec-
tions are weakened and eventually eliminated (Kano and 
Watanabe 2019). Up to date, experimental models to study 
postnatal synapse remodeling include structures such as the 
cerebellum and the dorsal lateral geniculate nucleus (Kano 
and Watanabe 2019). Alternatively, respiratory-related struc-
tures are also long being used to investigate mechanisms 
underlying postnatal networking and functional maturation. 
In this context, respiratory-related motor neurons, mainly 
hypoglossal motor neurons (HMNs), have been the object of 
study focused on changes in morphology, membrane recep-
tors, synaptic array and/or electrophysiological properties 
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lying behind functional and structural maturation (Marchetti 
et al. 2002; Greer and Funk 2005; Carrascal et al. 2015; 
Kanjhan et al. 2016b).
Respiration is critical during development, through-
out life, and must generate reliable, rhythmic motor out-
put through an elaborate system of control (Williams et al. 
2019a). However, the respiratory system is immature at 
birth and significant postnatal development occurs (Feld-
man et al. 2013). Thus, autonomic regions in the brainstem, 
which generate and control respiratory rhythm, are subjected 
to perinatal refinement for correct maturation. The normal 
functioning of the CNS is maintained by a fine-tuned bal-
ance between excitation and inhibition (Mody et al. 1994). 
The second postnatal week is a critical period in respira-
tory network development in the rat, when abrupt neuro-
chemical, metabolic, and physiological changes are evident. 
In this context, a sudden drop in expression of excitatory 
and heightened expression of inhibitory neurochemicals at 
P12–P13 occur in multiple respiratory-related brainstem 
nuclear groups of the rat including the hypoglossal motor 
nucleus (HN) (Gao et al. 2011). HMNs innervate the tongue 
and pharyngeal muscles supporting a number of vital func-
tions such as respiration, chewing, sucking, swallowing, 
and phonation. In the transition from the neonatal (P5–P8) 
to the adult stage, rat HMNs suffer a reduction of ~ 30% of 
the synaptic coverage (Sunico et al. 2005, 2010). Neverthe-
less, total number of synapses and number of excitatory and 
inhibitory boutons in the HN increased from birth to P20, 
followed by a decrease in adults (O’Kusky 1998). Strikingly, 
an excitatory/inhibitory imbalance in HMNs occurs during 
the critical period of postnatal development (P12–P13) (Gao 
et al. 2011). Given that, abnormalities in the normal devel-
opment of HMNs have been associated with sudden infant 
death syndrome (Konrat et al. 1992; Lavezzi et al. 2010) and 
obstructive sleep apnea (Remmers et al. 1978), deciphering 
molecular partners behind synaptic remodeling in the HN is 
also of clinical relevance.
A firm candidate to impact on excitatory/inhibitory 
refinement in the HN during postnatal maturation is the 
free radical nitric oxide (NO), which is synthesized by 
NO synthase (NOS). NO is a three-dimensional-acting 
diffusible factor “necessary” and “sufficient” for synap-
tic stripping of adult HMNs in pathological conditions 
(Sunico et al. 2005, 2010; Moreno-López and González-
Forero 2006; Montero et al. 2010; Moreno-López et al. 
2011; González-Forero and Moreno-López 2014). At 
pathological concentrations, NO acts as a synaptotoxic 
agent evoking withdrawal of stable synapses and avoid-
ing formation of new synaptic contacts on injured HMNs 
(Sunico et al. 2005; Moreno-López and González-Forero 
2006). Pathological NO at neonatal stage induces loss 
of both excitatory and inhibitory boutons even though 
excitatory was more profoundly affected than inhibitory 
synapses. But, remarkably, NO only affects excitatory 
inputs in adult rats (Sunico et al. 2010; Moreno-López 
et al. 2011; González-Forero and Moreno-López 2014). 
Mechanism of action by which NO triggers synaptic loss 
involves increased presynaptic myosin light chain phos-
phorylation (pMLC) preceding synapse destabilization 
(Sunico et al. 2010; Moreno-López et al. 2011). It is well 
known that pMLC triggers actomyosin contraction and 
neurite retraction (Luo 2000, 2002; Etienne-Manneville 
and Hall 2002). Nevertheless, the role of physiological NO 
in synaptic refinement of HMNs during postnatal develop-
ment remains elusive. Although, adult motor neurons lack 
in NOS (Moreno-López 2010), it is interesting to remark 
that transient expression of the neuronal isoform of NOS 
(NOS-I) occurs in HMNs at neonatal stage that fully dis-
appears before P21 (Vazquez et al. 1999). In this way, it 
has been postulated that under physiological nanomolar 
concentrations of NO, probably reached during postnatal 
maturation, a preferential loss of NO-sensitive inhibitory 
synapses might occur (Sunico et al. 2010).
Here, we hypothesize that endogenous NO determines 
excitatory/inhibitory balance in the HN during early post-
natal maturation. Thus, chronic administration of a NOS 
inhibitor (N(ω)-nitro-l-arginine methyl ester, l-NAME) dif-
ferentially affected excitatory and inhibitory inputs, then, 
altering excitatory/inhibitory ratio in the HN. Furthermore, 
l-NAME induced a reduction in the levels of pMLC in the 
nucleus, suggesting that mechanism by which endogenous 




Neonatal (P5) Wistar rats of either sex were obtained from 
an authorized supplier (Animal Supply Services, University 
of Cádiz, Cádiz, Spain). Animal care and handling followed 
the guidelines of the European Union Council (2010/63/EU, 
86/609/UE) on the use of laboratory animals. Experimental 
procedures were approved by the local Animal Care and 
Ethics Committee (University of Cádiz, Cádiz, Spain) and 
the Ministry of Agriculture, Fisheries and Rural Develop-
ment (Junta de Andalucía, Spain). Experimental animals 
were individually housed with their mother in cages with 
water and food pellets available ad libitum, at 21 ± 1 °C, 
with a 12-h light/dark cycle. Efforts were made to minimize 
the number of animals used and their suffering. All surgical 
processes were carried out under aseptic conditions. At least 
three animals per experimental condition were used. Data 
obtained from 27 pups were used for this study.
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Drug administration
After habituation for 48  h, the infusion system was 
implanted at P7 and, subsequently, pups were housed 
with their respective mother. Only animals which appro-
priately recovered after surgery were included in the study 
(27 of 35, ~ 75%). For drug delivery into the fourth ventri-
cle a stainless steel brain infusion cannula (30 gauge) was 
chronically implanted and connected by a Vinyl catheter 
(Alzet Brain infusion kit 3) to a osmotic minipump (vol-
ume: 100 μl, delivery rate: 0.25 μl/h; Alzet 1002, Durect, 
Cupertino, CA). Anesthetized (1.5–3% isoflurane mixed 
with 100%  O2) animals received intramuscularly atropine 
(0.2 mg/kg) and dexamethasone sodium phosphate (0.8 mg/
kg). The absence of withdrawal reflexes was considered a 
signal of sufficient deep anesthesia. Subsequently, pups were 
fixed with appropriated adaptors in a stereotaxic frame and 
the skin was incised longitudinally after disinfecting. The 
infusion cannula was carefully advanced throughout a drilled 
round window (0.5 mm in diameter) in the midline of the 
interparietal–occipital bones junction. Cannula was placed 
in parallel and close to the inner portion of the occipital 
bone (Fig. 1). The infusion system was finally attached to 
the skull by means of an instant adhesive gel (Loctite 454, 
Alzet) once the end of infusion cannula was positioned near 
to the fourth ventricle as previously performed (García-
Morales et al. 2015, 2019). Finally, a small incision was 
made at the base of the neck and stretched with a hemostat 
to facilitate implantation. The osmotic minipump was then 
placed subcutaneously through the opening. Afterward, all 
incisions were sutured with  Histoacryl® (Braun Surgical SA, 
Barcelona, Spain). All animals received one post-operative 
injection of penicillin (20,000 i.u./kg; i.m.) to prevent infec-
tion. Pyrazolone (0.1 mg/kg; i.m.) was given on awakening 
for post-operative analgesia. Drugs (l-/d-NAME) were dis-
solved in sterile saline and their concentration were adjusted 
to assure a chronic delivery of 180 mg/kg/day for 2 weeks.
Immunohistochemistry
Obtaining samples and immunohistochemistry processing 
have been performed as previously described with minimal 
differences (García-Morales et al. 2015, 2019). Juvenile 
(P21) rats were anesthetized with chloral hydrate (0.5 g/kg; 
i.p.), injected intraventricularly with heparin, and perfused 
transcardially first with phosphate buffer (PB) saline (PBS), 
followed by 4% paraformaldehyde in 0.1 M PB, pH 7.4, at 
4 °C. The brains were removed, postfixed for 2 h in the same 
fixative solution, and cryoprotected by overnight immersion 
in 30% sucrose in PB at 4 °C. Serial coronal sections (30-
μm thick) from brainstem were obtained using a cryostat 
and stored at − 20 °C in a cryoprotectant solution (glycerol 
and PBS, pH 7.4, 1:1 in volume) for latter immunolabeling.
Immunohistochemistry was performed against the vesicu-
lar glutamate transporter 2 (VGLUT2), the vesicular GABA/
glycine transporter (VGAT), to identified excitatory and 
inhibitory structures, respectively, and the non-phosphoryl-
ated form of neurofilament H (SMI32) as a motor neuron 
marker. Sections were rinsed in PBS and immersed in 2.5% 
(w/v) bovine serum albumin, 0.25% (w/v) sodium azide, and 
0.1% (v/v) Triton X-100 in PBS for 30 min, followed by over-
night incubation at 4 °C with the combination of VGLUT2/
SMI32 or VGAT/SMI32 antisera. Polyclonal primary anti-
bodies anti-VGAT (1:2000, Millipore Bioscience Research 
Reagents, Cat# AB5062P, RRID:AB_2301998), developed 
in rabbit; anti-VGLUT2 (1:2000, Millipore Bioscience 
Research Reagents, Cat# AB2251, RRID:AB_1587626) 
developed in guinea pig; and monoclonal primary antibody 
anti-SMI32 (1:8000, Covance Research Products Inc, Cat# 
SMI-32R-500, RRID:AB_509998) developed in mouse 
were used in this study. Subsequently, the tissue was rinsed 
3 times with PBS for 5 min each and incubated for 2 h at 
room temperature with the secondary antibodies, developed 
in donkey: anti-rabbit, anti-guinea pig, and anti-mouse IgGs 
labeled with the cyanine 2, 3, or 5 (Cy2, Cy3, Cy5) (1:400; 
Jackson ImmunoResearch Laboratories). Finally, sections 
were washed with PBS and mounted on slides with a solu-
tion containing propyl gallate (0.1 mM in PBS/glycerol, 1:9 
v/v). Animals and tissue were processed in parallel.
Sections were analyzed using an Olympus FV1000-MPE 










Fig. 1  Schematic illustrating the experimental protocol. An osmotic 
minipump, filled with l-NAME or d-NAME, was subcutaneously 
implanted and connected via a catheter to an infusion cannula fixed 
to the skull to deliver the drug into the fourth ventricle. Minipump 
implantation was performed at P7 and tissue extraction for histologi-
cal processing or western blotting analysis was performed at P21. 
Bottom, example of osmotic minipump connected to the infusion 
system extracted from an experimental animal. Minipump was then 
weighed to assure drug infusion. Scale bar, 10 mm
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primary antibodies resulted in no detectable staining. Images 
for quantification were acquired under a 40 × oil-immersion 
objective through a z-plane in which maximum antibody 
penetration was evidenced. For multichannel image acquisi-
tion, fluorophores were excited alternately. Pinholes were set 
to the same airy unit for each laser to obtain identical optical 
section thickness. For comparison between different exper-
imental conditions, images were acquired using the same 
settings. The perimeter, density, fluorescent intensity, and 
dimensions of immunolabeled structures were assessed with 
ImageJ 1.48 v (NIH). Only HMN somata at the level of the 
nucleus were included in the study. Images for quantification 
were flattened and background-filtered to enhance cluster 
outlines and an user-defined intensity threshold was applied 
to select puncta as previously described (Bannai et al. 2009; 
García-Morales et al. 2015). Briefly, to delineate synaptic 
structures, VGAT or VGLUT2 channel was first processed 
for background subtraction to obtain the maximum dynamic 
range of intensities (from 0 to 250). Next, images were 
subjected to a smoothing filter (same for all) and subse-
quently were binarized based on local differences in inten-
sity (Fig. 2). Only puncta reporting an area of > 0.04 μm2 
were taken as specific. Synaptic puncta apposed to HMNs 
somata and in the neuropil were differentially analyzed. 
Immunoreactive-puncta apposed to somata are presented as 
the number of synaptic structures per HMN and as linear 
density (puncta/100 μm of HMN perimeter). On the other 
hand, a grid composed by 16 squares (10 μm × 10 μm) was 
randomly distributed along the HN in each section to charac-
terize puncta in the neuropil. Only those synaptic structures 
included in squares that did not contain somata were ana-
lyzed (Fig. 2d). Area density (puncta/μm2) in neuropil was 
compared between treatments. Treatments were blinded for 
researcher who performed measures.
Western blotting
Tissue extraction and western blotting have been per-
formed as previously described (Sunico et  al. 2010). 
Rats (P7, P10, P18, and P21), untreated or treated with 
d-LAME or l-NAME (Fig.  1), were anesthetized by 
hypothermia (placing on ice for 10–15 min) and decapi-
tated, and their brainstems quickly removed. Dissection 
was in ice-cold (< 4 °C) sucrose artificial CSF (S-aCSF) 
bubbled with 95%  O2 and 5%  CO2. S-aCSF composition 
was as follows (in mM): 26  NaHCO3, 10 glucose, 3 KCl, 
1.25  NaH2PO4, 2  MgCl2, and 218 sucrose. Slicing and 
microdissection of HNs were both performed in ice-cold 
(< 4 °C) S-aCSF supplemented with protease (1 mM phe-
nylmethylsulfonyl fluoride, 10 mg/ml leupeptin, 10 mg/
ml pepstatin A, and 10 mg/ml aprotinin) and phosphatase 
inhibitors. Transverse slices (300–400-μm thick) were 
obtained using a vibroslicer (NVSL; WPI). Microdissected 
HNs were homogenized in lysis buffer [50 mM Tris/HCl, 
pH 7.4, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deox-
ycholate] supplemented with protease and phosphatase 
inhibitors using a 1-ml syringe. Equal amounts of protein 
were processed for SDS-PAGE and immunoblotting, using 
a specific antibody against pMLC (1:200; Santa Cruz 
Biotechnology, Cat# sc-17557, RRID:AB_670127) and 
MLC (1:200; Santa Cruz Biotechnology, Cat# sc-25618, 
RRID:AB_649811) developed in goat and rabbit, respec-
tively. Membranes were also probed with anti-α1-tubulin 
antibody (1:250,000; Sigma-Aldrich, Cat# T9026, 
RRID:AB_477593) developed in mouse, as a control for 







Fig. 2  Quantitative estimation of immunoreactive synaptic puncta. a 
High magnification confocal image of HN immunolabeled for VGAT 
(yellow) and the motoneuron marker SMI32 (blue). b, c After back-
ground subtraction, VGAT-ir puncta were manually isolated and 
smoothed (b) to delineate puncta using ImageJ software. Finally, 
images were converted into binary images (c). d As in a, but images 
was converted to a greyscale. Channel for SMI32 immunolabeling 
was omitted to analyze synaptic puncta. Grid composed by squares of 
100 μm2 used to quantify puncta density in neuropil using randomly 
sampled images is overimposed. Boxed area illustrates an analyzed 
region of interest. e, f As in b, c, for the boxed area in d. The size 
and number of dots in binary images were stored for posterior statisti-
cal analysis. Fluorescence intensity for each dot was measured from 
the original image in a or d. See “Materials and methods” for more 
details. Scale bar, 10 μm
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Statistics
Data are expressed as mean ± SEM. Unpaired two-tailed Stu-
dent’s t or Kolmogorov–Smirnov tests were used to com-
pare data or frequency distributions between two groups, 
respectively. When n ≤ 5, as in western blotting studies, the 
non-parametric Mann–Whitney U test was applied.
Results
l‑NAME impacts on inhibitory refinement
To assess the impact of endogenous NO on synaptic refine-
ment in the HN during early postnatal development, the 
broad-spectrum NOS inhibitor l-NAME (180 mg/kg/day) 
was chronically infused in the fourth ventricle from P7 to 
P21 by means of an osmotic minipump (Fig. 1). Immunohis-
tochemistry against the vesicular GABA/glycine transporter 
(VGAT) was performed to identify synaptic vesicle pools at 
inhibitory inputs, then it was used as a inhibitory synaptic 
marker. At P21, l-NAME-treated rats displayed an increase 
in both, the number (+ 24.4 ± 3.5%) and linear density 
(+ 9.2 ± 2.9%) of inhibitory puncta (VGAT-ir) apposed to 
HMNs somata, in comparison with animals which received 
the inactive stereoisomer d-NAME (Fig. 3a–d, Table 1). 
However, the size of VGAT-ir structures remains unaltered 
by the NOS inhibitor (Fig. 3e, Table 1). Interestingly, the 
reciprocal was observed at the neuropil. Whilst l-NAME did 
not impact on density of inhibitory puncta, VGAT-ir vesi-
cle pools were larger (+ 38.0 ± 3.7%) than after d-NAME-
treatment (Fig. 3f, g, Table 1). Finally, fluorescence inten-
sity of VGAT-ir structures was only affected (+ 38.2 ± 3.3%) 
by NOS inhibitor in puncta located at the neuropil but not 
in those around HMN somata (Fig. 3h). In summary, a net 
increase of the inhibitory influence in the HN was noted at 
P21 after l-NAME-treatment. This alteration was accounted 
by an increase in the number of inhibitory puncta around 
HMN perikarya together with an enhancement of the size of 
vesicle pools in the neuropil. These outcomes suggest that 
endogenous NO is unfavorable for some inhibitory inputs in 
the HN during postnatal maturation.
l‑NAME affects excitatory rearrangement
Immunohistochemistry against the vesicular glutamate 
transporter 2 (VGLUT2) was performed to label a sub-
type of excitatory synaptic inputs. In contrast to what hap-
pened with inhibitory puncta, l-NAME-treatment induced 
a reduction in both, the number (− 15.9 ± 1.7%) and linear 
density (− 19.6 ± 1.7%) of VGLUT2-ir puncta apposed to 
HMN somata, in comparison with animals which received 
the inactive stereoisomer d-NAME (Fig. 4a–d, Table 2). 
Interestingly, the size of excitatory vesicle pools was 
increased (+ 4.5 ± 1.8%) by the NOS inhibitor (Fig. 4e, 
Table  2). At the neuropil, l-NAME affected density 
(− 17.6 ± 2.4%), but not size, of VGLUT2-ir structures 
(Fig. 4f, g, Table 2). Finally, fluorescence intensity of excita-
tory puncta was only affected (+ 6.7 ± 1.9%) by l-NAME 
in synaptic vesicle pools around HMNs somata (Fig. 4h). 
Thus, a reduction in the excitatory signaling in the HN was 
noted at P21 after l-NAME-treatment. This alteration was 
accounted by a decline in the number of excitatory puncta 
around HMN perikarya, although a partial compensatory 
effect might be expected by increase in the synaptic vesicle 
pool size, together with a decrease in puncta density in the 
neuropil. Altogether, results support that physiologically 
synthesized NO has a positive impact on certain excitatory 
inputs in the HN during postnatal maturation.
l‑NAME‑induced alterations in excitatory/inhibitory 
balance
Next, we analyzed the effect of the NOS inhibitor on the 
excitatory/inhibitory ratio in the HN. After 2-week treat-
ment with l-NAME, the excitatory/inhibitory balance 
was strongly altered in comparison with ratio observed 
in d-NAME-treated animals (Table 3). Whilst the num-
ber (+ 55.4 ± 2.8%) and linear density (+ 56.3 ± 2.9%) 
of VGLUT2-ir puncta were higher than VGAT-ir ones 
apposed to HMNs in d-NAME-treated rats, this ratio was 
strongly reduced (number: + 5.0 ± 2.1%; linear density: 
+ 15.1 ± 2.4%) under l-NAME-treatment (Table 3). Given 
that, the mean size of excitatory structures near perikarya 
was increased by the NOS inhibitor (Fig. 4e, Table 2), 
one possibility arises that size increase in synaptic vesi-
cle pools at excitatory inputs could compensate in some 
degree l-NAME-induced alterations in excitatory/inhibi-
tory balance on HMNs by increasing the number of dispos-
able synaptic vesicles. In this context, the mean total area 
of VGLUT2-ir and VGAT-ir puncta was the result of the 
multiplication of the mean size of synaptic structures by 
the mean number of puncta per HMN (Table 3). Thus, the 
ratio of total area of VGLUT2/VGAT puncta was 0.96 in 
d-NAME versus 0.68 in l-NAME-treated animals, which 
reports a reduction of ~ 30% after application of the NOS 
inhibitor (Table 3). At the neuropil, the density of excita-
tory versus inhibitory structures were robustly reduced after 
l-NAME- (+ 133.3 ± 0.7%) relative to d-NAME-treatment 
(+ 198.0 ± 0.9%) (Table 3). Furthermore, l-NAME induced 
a decrease (~ − 45%) of the area occupied by VGLUT2-ir 
in relation to VGAT-ir puncta (Table 3). This agrees with 
reduction observed in the density of excitatory structures 
(Fig. 4f, Table 2) in parallel to increase in the size of inhibi-
tory ones (Fig. 3g, Table 1) induced by the NOS inhibitor. 
Taken together, outcomes agree with the hypothesis that 









































































































































































































































Fig. 3  l-NAME-treatment increases inhibitory puncta apposed to 
HMNs somata. a High magnification confocal images showing two 
SMI32-ir HMNs (blue) and surrounding VGAT-positive puncta (red) 
from P21 rats treated with d-NAME (top) or l-NAME (bottom). 
Scale bars, 10 μm. b, c Number of VGAT-ir puncta per HMN (b) and 
per 100 μm of somata perimeter (c) after d-NAME (blue) or l-NAME 
(green) treatment. d Frequency histogram of the number of VGAT-
ir puncta per HMN receiving indicated treatments. Bin, 2 puncta/
HMN. Dashed lines represent Gaussian curve fits for each treatment 
(d-NAME, r2 = 0.93; l-NAME, r2 = 0.89). Statistic output for Kol-
mogorov–Smirnov test between the two distributions is stated in the 
plot. e Frequency histogram of the size of VGAT-ir puncta apposed 
to HMNs somata under indicated treatments. Bin, 0.1 μm2. Inset, box 
plot of puncta size after d-NAME or l-NAME treatment. f Number 
of VGAT-ir puncta per μm2 in the neuropil after stated treatments. 
g As in e but for puncta analyzed in the neuropil. h Fluorescence 
(Fluor.) intensity of analyzed VGAT-ir puncta apposed to HMNs and 
in the neuropil after d-NAME or l-NAME-treatment. Box plots show 
median (white line) and the 25–75% range as box, the whiskers indi-
cate 5–95% range. The number of analyzed HMNs (b–d), regions of 
interest in the neuropil (f) or puncta (e, g, h) are presented in paren-
theses. *p < 0.05, **p < 0.01, ***p < 0.001; n.s. not significant; by 
Student t test
Table 1  VGAT-ir puncta in the 
HN
*p < 0.05, **p < 0.01, ***p < 0.001 by Student t test
a Number of puncta per HMN somata, bnumber of puncta per 100 μm, cnumber of puncta per μm2
Treatment Somatic puncta Neuropil puncta
Numbera Linear  densityb Size (μm2) Area  densityc Size (μm2)
d-NAME 11.71 ± 0.42 13.37 ± 0.38 0.71 ± 0.02 0.057 ± 0.002 1.08 ± 0.03
l-NAME 14.57 ± 0.41*** 14.60 ± 0.39* 0.71 ± 0.02 0.060 ± 0.003 1.49 ± 0.04***
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Fig. 4  l‑NAME‑trEAtMENt rEducEs ExcitAtory puNctA iN thE 
hN a High magnification confocal images showing two SMI32-ir 
HMNs (blue) and surrounding VGLUT2-positive puncta (green) 
from P21 rats treated with d-NAME (left) or l-NAME (right). 
Scale bars, 10  μm. b, c Number of VGLUT2-ir puncta per HMN 
b and per 100  μm of somata perimeter c after d-NAME (blue) or 
l-NAME (green) treatment. d Frequency histogram of the number 
of VGLUT2-ir puncta per HMN receiving indicated treatments. Bin, 
2 puncta/HMN. Dashed lines represent Gaussian curve fits for each 
treatment (d-NAME, r2 = 0.90; l-NAME, r2 = 0.95). Statistic output 
for Kolmogorov–Smirnov test between the two distributions is stated 
in the plot. e Frequency histogram of the size of excitatory puncta 
apposed to HMNs somata under indicated treatments. Bin, 0.1 μm2. 
Inset, box plot of puncta size after d-NAME or l-NAME-treatment. 
f Number of VGLUT2-ir puncta per μm2 in the neuropil after stated 
treatments. g As in e but for puncta analyzed in the neuropil. h Fluo-
rescence (Fluor.) intensity of analyzed VGLUT2-ir puncta apposed 
to HMNs and in the neuropil after d-NAME- or l-NAME-treatment. 
Box plots show median (white line) and the 25–75% range as box, 
the whiskers indicate 5–95% range. The number of analyzed HMNs 
(b–d), regions of interest in the neuropil (f) or puncta (e, g, h) are 
presented in parentheses. *p < 0.05, **p < 0.01, ***p < 0.001; n.s. not 
significant; by Student t test
Table 2  VGLUT2-ir puncta in 
the HN
*p < 0.05, **p < 0.01, ***p < 0.001 by Student t test
a Number of puncta per HMN somata, bnumber of puncta per 100 μm, cnumber of puncta per μm2
Treatment Somatic puncta Neuropil puncta
Numbera Linear  densityb Size (μm2) Area  densityc Size (μm2)
d-NAME 18.2 ± 0.33 20.9 ± 0.39 0.44 ± 0.007 0.17 ± 0.005 0.45 ± 0.006
l-NAME 15.3 ± 0.31*** 16.8 ± 0.35*** 0.46 ± 0.008** 0.14 ± 0.004*** 0.44 ± 0.006
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endogenous NO controls excitatory/inhibitory balance by 
promoting maintenance and/or gain of glutamatergic inputs 
and destabilization of GABA/glycinergic synapses during 
early postnatal maturation of the HN.
l‑NAME alters the size of HMNs somata
When the number of synaptic puncta was expressed rela-
tive to motor neuron size, l-NAME-induced linear density 
alterations were attenuated for inhibitory puncta or strength-
ened for excitatory ones in comparison to absolute number 
of synaptic structures expressed per HMN. That is, whereas 
the number of VGAT-ir puncta increased in ~ 25% under 
l-NAME-treatment, linear density only changed in ~ 9% 
(Fig. 3b, c, Table 1). On the other hand, NOS inhibitor-
induced reduction in the number of excitatory structures 
around HMNs (~ − 16%) was accentuated (~ − 20%) when 
relativized to perykaria perimeter (Fig. 4b, c, Table 2). These 
observations argued on a presumably effect of l-NAME on 
somata size. At this point, it is interesting to remark that 
HMNs somata size experienced an increase of approxi-
mately 40% from P1 to P21 (Williams et al. 2019a, b). Thus, 
we hypothesized that l-NAME effects HMNs development 
by impacting on normal morphological changes, including 
adjustment in somata size, during postnatal development.
In this way, the somata perimeter of SMI32-immu-
nolabeled HMNs was measured at P21 in d-NAME- and 
l-NAME-treated rats. Strikingly, the mean perimeter of 
HMNs perykaria after d-NAME-treatment (87.5 ± 1.2 μm) 
was lower than after administration of the NOS inhibitor 
(94.5 ± 1.1 μm) (Fig. 5a, b). This involved a displacement to 
the right in the frequency distribution of the HMNs somata 
perimeter (Fig. 5c). Therefore, these outcomes support that 
endogenous NO not only regulates excitatory/inhibitory bal-
ance in the HN, but also control morphological changes of 
HMNs during postnatal development.
l‑NAME reduces pMLC levels in the HN
It is well known that pMLC triggers actomyosin contraction 
and neurite retraction (Luo 2000, 2002; Etienne-Manneville 
and Hall 2002). In this context, we recently proposed that 
pathological NO triggers synaptic loss by promoting MLC 
phosphorylation at the presynaptic counterpart preceding 
Table 3  VGLUT2/VGAT ratio 
in the HN
Ratio and mean values (in parentheses) for VGLUT2/VGAT-ir puncta
a Number of puncta per HMN somata, bnumber of puncta per 100 μm, c,eratio of the total area of puncta per 
HMN  somatac or per μm2e, dnumber of puncta per 100 μm2, evalues in parentheses are in μm2
Treatment Somatic puncta Neuropil puncta
Numbera Linear  densityb Area/HMNc Area  densityd Area/μm2e
d-NAME 1.6 (18.2/11.7) 1.6 (20.9/13.4) 0.96 (8.0/8.3) 3.0 (0.17/0.057) 1.3 (0.08/0.06)
l-NAME 1.1 (15.3/14.6) 1.2 (16.8/14.6) 0.68 (7.0/10.3) 2.3 (0.14/0.060) 0.7 (0.06/0.09)


















































Fig. 5  l-NAME-treatment impacts on HMNs somata perimeter. a 
High magnification confocal images showing two SMI32-ir HMNs 
from P21 rats treated with d-NAME (top) or l-NAME (bottom). Dot-
ted lines indicate the measured perimeter per each HMN. Scale bars, 
10 μm. b Box plot of the perimeter of analyzed HMNs after d-NAME 
(blue) or l-NAME (green) treatment. Box plot shows median (white 
line) and the 25–75% range as box, the whiskers indicate 5–95% 
range. c Frequency histogram of the HMNs somata perimeter after 
receiving indicated treatments. Bin, 5  μm. Solid lines represent 
Gaussian curve fits for each treatment (d-NAME, r2 = 0.92; l-NAME, 
r2 = 0.96). Statistic output for Kolmogorov–Smirnov test between 
the two distributions is stated in the plot. The number of analyzed 
HMNs (b, c) are presented in parentheses. *p < 0.05, **p < 0.01, 
***p < 0.001; n.s. not significant; by Student t test
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synapse destabilization (Sunico et al. 2010; Moreno-López 
et al. 2011). Thus, we look for evidence that the mecha-
nism of action by which NO controls synaptic refinement 
in the HN during postnatal development involves pMLC, 
as an indirect indicator of actomyosin contraction. First, 
we studied the levels of pMLC at different time points 
of interest during early perinatal progress. Whilst pMLC 
levels in microdissected HNs were kept stable at P7 
(100 ± 0.0%) and P10 (107.3 ± 19.2%), a significant increase 
in the phosphorylated form of MLC was observed at P18 
(134.3 ± 20.8%) and P21 (272.8 ± 28.1%) (Fig. 6A). Finally, 
at P21, l-NAME-treatment from P7 to P21, reduced pMLC 
levels as relativized to α-tub (− 49.5 ± 9.7%) and MLC 
(− 47.2 ± 9.2%), although did not alter total amount of MLC 
(− 12.1 ± 10.4%) in the HN, in comparison to d-NAME-
treated rats (Fig. 6b). Therefore, these results open the pos-
sibility that control by NO of synaptic maturation during 
early postnatal development could involve, at least in part, 
activity regulation of the actomyosin contraction apparatus.
Discussion
We report here that endogenous NO tunes excitatory/inhibi-
tory balance in the HN in the P7–P21 early postnatal inter-
val. Synthesized NO during postnatal development seems 
to act as an anti-synaptotrophic factor or a synaptotoxin for 
certain inhibitory synapses, whilst it favors stabilization and/
or gain of some excitatory inputs thus supporting a synapto-
trophic action of NO on this type of synapses. Furthermore, 
NO impacts on morphological maturation of HMNs during 
the neonatal stage by regulating, at least, somata size. The 
mechanism of action by which endogenous NO regulates 
postnatal maturation of the HN could involve MLC phos-
phorylation and subsequent modulation of the actomyo-
sin contraction apparatus. Since deviations in the normal 
development of HMNs have been related with sudden infant 
death syndrome (Konrat et al. 1992; Lavezzi et al. 2010) and 
obstructive sleep apnea (Remmers et al. 1978), our data sug-
gest that alterations in NOS expression and/or NO synthesis 
during this critical period could lie behind both pathological 
conditions.
Previous studies find a net reduction of inhibitory inputs 
incoming to HMNs in the transition interval from neonatal 
to adult stages (Sunico et al. 2010; Paik et al. 2019). On the 
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Fig. 6  l-NAME reduces pMLC levels in the HN during early postna-
tal development. a Western blots (top) and plot showing pMLC lev-
els, relativized to α-tubulin (α-tub) taken as an internal loading ref-
erence, in microdissected HNs from rats at the indicated ages after 
birth. Values obtained at P7 was taken as 1. b Western blots (top) 
and plot of pMLC, MLC, and α-tub showing that pMLC, but not 
MLC, levels at P21 were reduced under l-NAME- in comparison to 
d-NAME-treatment. Four rats per treatment are shown in immunob-
lots. Mean values obtained for d-NAME was taken as 100%. Number 
of animals per time point or treatment are indicated in parentheses. 
Symbols indicate values obtained from each animal. Mean ± SEM 
are also shown in the plots. *p < 0.05, **p < 0.01, n.s. not significant; 
non-parametric Mann–Whitney U test
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synapses increases with differentiation up to P20 (Davidoff 
and Galabov 1975; Paik et al. 2019). Interestingly, postna-
tal synaptic refinement in the HN consists in progressive 
and regressive phases of synaptogenesis involving an initial 
increase in density and total number for asymmetric and 
symmetric synapses from birth to P20, followed by a sig-
nificant decrease of both in adults (O’Kusky 1998). Con-
sistently, here, d-NAME-treated rats showed an increase 
in the linear density of somatic VGLUT2-ir puncta at P21 
(20.9 ± 0.39/100 μm) as compared with that we obtained 
from untreated HMNs at P7 (6.6 ± 0.49/100 μm) (Sunico 
et al. 2010). However, d-NAME-treated animals displayed at 
P21 a reduction, rather than an increase, in the linear density 
of somatic inhibitory puncta (13.26 ± 0.34/100 μm) relative 
to that we previously reported at P7 (19.9 ± 0.8/100 μm) 
(Sunico et al. 2010). The reason for this apparent discrep-
ancy may lie behind different analytical procedures per-
formed, i.e. electron vs confocal microscopy. In this line of 
argument, single VGAT-ir puncta does not necessarily corre-
spond to an individual synaptic bouton because of VGAT-ir 
vesicles pools from adjacent boutons could be considered as 
a unique puncta under confocal analysis.
Many molecules are involved in synaptogenic events dur-
ing nervous system maturation (Benson et al. 2001; Garner 
et al. 2002; Yamagata et al. 2003; Stevens et al. 2007). NO 
is a candidate diffusible molecule linking spatiotemporally 
events that occur in presynaptic and postsynaptic structures 
to refine synaptic contacts. NO participates in projection 
refinement during development (Wu et al. 1994) and in 
synapse loss suffered by HMNs after motor nerve injury 
and in an animal model of amyotrophic lateral sclerosis 
(ALS) (Sunico et al. 2005, 2010, 2011; Moreno-López and 
González-Forero 2006; Montero et al. 2010; Moreno-López 
et al. 2011). In the opposite direction, NO promotes for-
mation of new synapses in developing olfactory receptor 
neurons (Roskams et al. 1994) and in hippocampal organo-
typic slice cultures (Nikonenko et al. 2003). Furthermore, 
transient expression of NOS-I occurs in HMNs at neonatal 
stage that fully disappears before P21 (Vazquez et al. 1999). 
Accordingly, chronic treatment with the NOS inhibitor 
l-NAME resulted in a reduction in the number and density 
of excitatory puncta around HMNs somata and in the neu-
ropil but, in contrast, caused an increase in inhibitory puncta 
apposed to HMNs perikarya at P21. These outcomes are 
consistent with a synaptotrophic action of NO on excitatory 
puncta by promoting net stabilization of excitatory puncta 
and/or formation of new synaptic structures, but, in con-
trast, NO seems to act as an anti-synaptotrophic or synap-
totoxic factor for VGAT-ir puncta favoring synaptic disrup-
tion and/or loss. In this way, pathological concentrations of 
NO induced a reduction in both VGAT-ir and VGLUT2-ir 
puncta around neonatal HMNs which actually represented 
a loss of inhibitory and excitatory boutons from HMNs 
even though excitatory were more profoundly affected than 
inhibitory synapses (Sunico et al. 2010). Strikingly, patho-
logically induced NOS-I expression in adult HMNs led to a 
NO-triggered and selective loss of excitatory inputs (Sunico 
et al. 2010). Therefore, results obtained in the present work 
support our preceding hypothesis that under physiological 
concentrations of NO, as that probably reached during post-
natal maturation, a predominant loss of NO-sensitive inhibi-
tory synapses could occur throughout perinatal development 
(Sunico et al. 2010).
The source of NO-controlling synaptic refinement during 
this interval is likely the transient expression of NOS-I in 
HMNs occurring during this critical period (Vazquez et al. 
1999), although another different origins cannot be fully 
discarded. This idea is strengthened by several findings: (1) 
it is well known that adult motor neurons do not express 
NOS (Moreno-López 2010), and, interestingly, l-NAME 
administration for 7 days in adult rats did not affect synaptic 
arrangement in the HN and HMNs (Sunico et al. 2005); (2) 
de novo expression of NOS-I in adult HMNs induced by 
axonal injury or by viral transduction of intact HMNs, both 
induced a change in excitatory/inhibitory balance on motor 
neurons that was reverted/avoided, at least in part, by inter-
fering with NOS-I/NOS (Sunico et al. 2010; Montero et al. 
2010; Moreno-López et al. 2011); and (3) in pre-sympto-
matic and early-symptomatic ALS mice, de novo expression 
of NOS occurs in motor neurons and glia concomitantly with 
an excitatory/inhibitory unbalance in HMNs which was par-
tially restored/avoided by chronic treatment with l-NAME 
(Moreno-López et al. 2011; Sunico et al. 2011).
Mechanism of action by which endogenous NO con-
trols synaptic dynamic during postnatal development 
could involve modulation of the actomyosin contraction 
apparatus. In this context, MLC phosphorylation triggers 
actomyosin contraction and neurite retraction (Luo 2000, 
2002; Etienne-Manneville and Hall 2002). In this line, the 
small Rho GTPase RhoA and its major effector Rho kinase 
(ROCK) mediates fiber contraction by enhancing pMLC. 
RhoA/ROCK signaling, directly and/or indirectly activating 
MLC-kinase, phosphorylates MLC. It then induces actomyo-
sin contraction and neurite outgrowth inhibition/retraction 
disturbing spine formation and maintenance. By decreasing 
synaptic connectivity during development, this mechanism 
has been proposed to underlie mental retardation (Newey 
et al. 2005). NO-dependent increase in pMLC levels has 
been reported in the HN and in the synaptic coverage of 
HMNs preceding NO-triggered synapse loss suffered by sick 
motor neurons (Sunico et al. 2010, 2011; Moreno-López 
et al. 2011). Here, increased levels of pMLC were measured 
in the HN at P18 and P21, however, chronic application of 
the NOS inhibitor avoided pMLC rise, thus supporting that 
NO could regulate actomyosin contraction during postna-
tal maturation of the HN. Whether pMLC increase occurs 
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in synaptic structures before inputs remodeling and/or it is 
involved in NO-mediated regulation of HMNs morphology 
remain elusive.
HMNs participate in a number of functions such as respi-
ration, chewing, sucking, swallowing, and phonation. Then, 
the HN receives afferents from pre-motor nuclei coding for 
oro-facial functions, thus involving many other structures 
coding respiratory-unrelated activity (Travers and Norgren 
1983; Borke et al. 1983; Takada et al. 1984; Ugolini et al. 
1987; Aldes 1990; Manaker et al. 1992). In this way, whether 
endogenous NO affects synaptic afferents from respiratory-
related and/or -unrelated pre-motor structures is a matter that 
merit further investigation. This, together with subtle altera-
tions in synaptic arrangement found after presumable partial 
inhibition (Moreno-López et al. 2004) of NOS-I in the HN, 
could explain why alterations in the breathing pattern of 
l-NAME-treated pups were not evidenced. In addition, the 
emergence of still to discover compensatory mechanisms in 
response to chronic inhibition of NOS cannot be discarded.
Administration route in our experiments ensures that 
l-NAME can affect most brain structures that express NOS. 
For example, transient expression of NOS during postnatal 
development includes brain structures such as cerebral cor-
tex (Vercelli et al. 1999; Imura et al. 2005) and hippocampus 
(Chung et al. 2004), lateral geniculate nucleus (Cramer et al. 
1995) and superior colliculus (Mize et al. 1997), cerebellum 
(Li et al. 1997), and olfactory bulb (Samama and Boehm 
1996), among others. In this context, NO is believed to act 
as a retrograde messenger to stabilize synaptic connections 
via an activity-dependent mechanism (Williams et al. 1994). 
Therefore, it is possible that l-NAME infusion from P7 to 
P21 might alter networking in these structures, subsequently 
leading to some distortion in the correct acquisition of rel-
evant functions such as visual processing, smell, learning 
and memory, or other associative and higher level tasks.
Dysregulation of NO synthesis and/or NOS expression 
has been suggested to lie behind synaptic dysfunction asso-
ciated with cognitive decline in many neurological condi-
tions (Moreno-López et al. 2011). At the neonatal stage, 
transient expression of NOS in HMNs seems to be essential 
for normal maturation of synaptic arrangement in the HN. 
Interestingly, HMNs development impairment is related 
with sudden infant death syndrome (Konrat et al. 1992; 
Lavezzi et al. 2010) and obstructive sleep apnea (Rem-
mers et al. 1978). Normal anatomical maturation of HMNs 
(Cameron and Nunez-Abades 2000; Carrascal et al. 2005, 
2015; Kanjhan et al. 2016a, b; Williams et al. 2019a, b) 
might be impaired by disruption of NOS transient expression 
in motor neurons. It can contribute to abnormal HN size, 
hypoplasia, and immaturity of HMNs found in sudden infant 
death syndrome (Konrat et al. 1992; O’Kusky and Norman 
1995; Ottaviani et al. 2006; Lavezzi et al. 2010). In con-
trast, since NO over-production is cytotoxic (Moreno-López 
2010; Moreno-López et al. 2011), transitory over-expres-
sion of NOS might affect HMN viability. In this context, 
the number of apoptotic cells in the HN was enhanced in 
sudden unexpected death in infancy (Ambrose et al. 2018). 
Furthermore, dysregulation of NOS expression could be 
involved in synaptic alterations in the HN observed in sud-
den infant death syndrome (O’Kusky and Norman 1995). 
At the electrophysiological level, developmental changes in 
passive and active membrane properties determine mature 
HMNs excitability (Cameron and Nunez-Abades 2000; Car-
rascal et al. 2005, 2015; Greer and Funk 2005). Thus, input 
resistance and rheobase (minimal current to elicit an action 
potential) decrease, by at least developmental increase in 
the expression of a “leak” potassium current mediated by 
TASK1 channels (Talley et al. 2000; Greer and Funk 2005). 
In addition, inward rectification current (Ih) up-regulates 
during postnatal development. Interestingly, NO increases 
HMNs excitability by facilitating Ih current, and enhances 
input resistance and reduces rheobase (González-Forero 
et al. 2007; Montero et al. 2008) by at least inhibiting and/
or impairing plasma membrane insertion of TASK1 channels 
(González-Forero et al. 2007; García-Morales et al. 2019). 
Therefore, dysregulation of NOS expression during this key 
period could lie behind HMN malfunctioning contributing to 
sudden infant death. Further, under distortion of transitory 
expression of NOS, the ratio excitatory/inhibitory inputs 
might be reduced leading to hypoactive HMNs after matu-
ration which could enhance the probability to suffer obstruc-
tive sleep apnea. Accordingly, hypoglossal nerve stimulation 
is proposed as an effective long-term therapy in selected 
patients of this pathology (Kent et al. 2019; Gottlieb and 
Punjabi 2020). Altogether, it would be interesting to inves-
tigate whether disturbance of transient expression of NOS is 
a feasible etiopathogenic event underlying these pathologies.
Acknowledgements We thank Dr. María Jesús Medialdea-Wandossell 
for her help in western blotting analysis and Mr. Antonio Torres for his 
skillful technical assistance.
Author contributions BML conceptualized, designed the study, and 
wrote the paper. FP performed experiments, data analysis, and figures.
Funding This work has been co-financed by the European Union under 
the 2014–2020 ERDF Operational Programme and by the Department 
of Economy, Knowledge, Business and University of the Regional 
Government of Andalusia. Project reference: FEDER-UCA18-108475. 
Other funding grants: BFU2015-71422-R (MINECO/FEDER) and 
PID2019-110960GB-I00 (MICINN) from the Spain’s Government 
and LI19/10IN-CO21 from INiBICA to BML.
Availability of data and material The datasets generated and/or ana-
lyzed during the current study are available from the corresponding 
authors on reasonable request.
2882 Brain Structure and Function (2020) 225:2871–2884
1 3
Compliance with ethical standards 
Conflict of interest The authors declare they have no conflict of inter-
est.
Ethical statement Animals were obtained from an authorized supplier 
(Animal Supply Services, University of Cádiz, Cádiz, Spain). Ani-
mal care and handling followed the guidelines of the European Union 
Council (2010/63/EU, 86/609/UE) on the use of laboratory animals. 
Experimental procedures were approved by the local Animal Care and 
Ethics Committee (University of Cadiz, Cadiz, Spain) and the Ministry 
of Agriculture, Fisheries and Rural Development (Junta de Andalucía, 
Spain).
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
Aldes LD (1990) Topographically organized projections from the 
nucleus subceruleus to the hypoglossal nucleus in the rat: A 
light and electron microscopic study with complementary axonal 
transport techniques. J Comp Neurol 302:643–656. https ://doi.
org/10.1002/cne.90302 0318
Ambrose N, Waters KA, Rodriguez ML et al (2018) Neuronal apoptosis 
in the brainstem medulla of sudden unexpected death in infancy 
(SUDI), and the importance of standardized SUDI classification. 
Forensic Sci Med Pathol 14:42–56. https ://doi.org/10.1007/s1202 
4-018-9954-1
Bannai H, Lévi S, Schweizer C et al (2009) Activity-dependent tun-
ing of inhibitory neurotransmission based on GABAAR diffusion 
dynamics. Neuron 62:670–682. https ://doi.org/10.1016/j.neuro 
n.2009.04.023
Benson DL, Colman DR, Huntley GW (2001) Molecules, maps and 
synapse specificity. Nat Rev Neurosci 2:899–909. https ://doi.
org/10.1038/35104 078
Borke RC, Nau ME, Ringler RL (1983) Brain stem afferents of hypo-
glossal neurons in the rat. Brain Res 269:47–55. https ://doi.
org/10.1016/0006-8993(83)90961 -7
Cameron WE, Nunez-Abades PA (2000) Physiological changes accom-
panying anatomical remodeling of mammalian motoneurons dur-
ing postnatal development. Brain Res Bull 53:523–527
Carrascal L, Nieto-Gonzalez JL, Cameron WE et al (2005) Changes 
during the postnatal development in physiological and anatomi-
cal characteristics of rat motoneurons studied in vitro. Brain Res 
Rev 49:377–387
Carrascal L, Nieto-Gonzalez JL, Pardillo-Diaz R et al (2015) Time 
windows for postnatal changes in morphology and membrane 
excitability of genioglossal and oculomotor motoneurons. World 
J Neurol 5:113–131. https ://doi.org/10.5316/wjn.v5.i4.113
Chung YH, Kim YS, Lee WB (2004) Distribution of neuronal nitric 
oxide synthase-immunoreactive neurons in the cerebral cortex 
and hippocampus during postnatal development. J Mol Histol 
35:765–770. https ://doi.org/10.1007/s1073 5-004-0667-2
Cramer KS, Moore CI, Sur M (1995) Transient expression of NADPH-
diaphorase in the lateral geniculate nucleus of the ferret during 
early postnatal development. J Comp Neurol 353:306–316. https 
://doi.org/10.1002/cne.90353 0211
Davidoff M, Galabov G (1975) Uber die postnatale entwicklung des 
hypoglossuskerns der ratte (The postnatal development of the 
hypoglossal nucleus in the rat). Z Mikrosk. Anat. Forsch Abt 
2(89):615–631
Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. 
Nature 420:629–635
Feldman JL, Del Negro CA, Gray PA (2013) Understanding the rhythm 
of breathing: so near, yet so far. Annu Rev Physiol 75:423–452
Gao XP, Liu QS, Liu Q, Wong-Riley MTT (2011) Excitatory-inhibitory 
imbalance in hypoglossal neurons during the critical period of 
postnatal development in the rat. J Physiol 589:1991–2006. https 
://doi.org/10.1113/jphys iol.2010.19894 5
García-Morales V, Montero F, González-Forero D et al (2015) Mem-
brane-derived phospholipids control synaptic neurotransmission 
and plasticity. PLoS Biol 13:e1002153. https ://doi.org/10.1371/
journ al.pbio.10021 53
García-Morales V, Rodríguez-Bey G, Gómez-Pérez L et al (2019) Sp1-
regulated expression of p11 contributes to motor neuron degenera-
tion by membrane insertion of TASK1. Nat Commun 10:3784. 
https ://doi.org/10.1038/s4146 7-019-11637 -4
Garner CC, Zhai RG, Gundelfinger ED, Ziv NE (2002) Molecular 
mechanisms of CNS synaptogenesis. Trends Neurosci 25:243–250
González-Forero D, Moreno-López B (2014) Retrograde response in 
axotomized motoneurons: Nitric oxide as a key player in trigger-
ing reversion toward a dedifferentiated phenotype. Neuroscience 
283:138–165
González-Forero D, Portillo F, Gómez L et al (2007) Inhibition of 
resting potassium conductances by long-term activation of the 
NO/cGMP/protein kinase G pathway: a new mechanism regulat-
ing neuronal excitability. J Neurosci 27:6302–6312. https ://doi.
org/10.1523/JNEUR OSCI.1019-07.2007
Goodman CS, Shatz CJ (1993) Developmental mechanisms that gener-
ate precise patterns of neuronal connectivity. Cell 72:77–98
Gottlieb DJ, Punjabi NM (2020) Diagnosis and management of 
obstructive sleep apnea: a review. JAMA J Am Med Assoc 
323:1380–1400. https ://doi.org/10.1001/jama.2020.3514
Greer JJ, Funk GD (2005) Perinatal development of respiratory 
motoneurons. Respir Physiol Neurobiol 149:43–61. https ://doi.
org/10.1016/j.resp.2005.03.017
Imura T, Kanatani S, Fukuda S et al (2005) Layer-specific produc-
tion of nitric oxide during cortical circuit formation in postnatal 
mouse brain. Cereb Cortex 15:332–340. https ://doi.org/10.1093/
cerco r/bhh13 5
Kanjhan R, Fogarty MJ, Noakes PG, Bellingham MC (2016a) Devel-
opmental changes in the morphology of mouse hypoglossal 
motor neurons. Brain Struct Funct 221:3755–3786. https ://doi.
org/10.1007/s0042 9-015-1130-8
Kanjhan R, Noakes PG, Bellingham MC (2016b) Emerging roles of 
filopodia and dendritic spines in motoneuron plasticity during 
development and disease. Neural Plast 2016:3423267. https ://
doi.org/10.1155/2016/34232 67
Kano M, Watanabe T (2019) Developmental synapse remodeling in the 
cerebellum and visual thalamus. F1000Research 8:1191
Kent DT, Carden KA, Wang L et al (2019) Evaluation of hypoglos-
sal nerve stimulation treatment in obstructive sleep apnea. 
2883Brain Structure and Function (2020) 225:2871–2884 
1 3
JAMA Otolaryngol Head Neck Surg 145:1044–1052. https ://doi.
org/10.1001/jamao to.2019.2723
Konrat G, Halliday G, Sullivan C, Harper C (1992) Preliminary evi-
dence suggesting delayed development in the hypoglossal and 
vagal nuclei of SIDS infants: a necropsy study. J Child Neurol 
7:44–49. https ://doi.org/10.1177/08830 73892 00700 108
Lavezzi AM, Corna M, Mingrone R, Matturri L (2010) Study of the 
human hypoglossal nucleus: normal development and morpho-
functional alterations in sudden unexplained late fetal and infant 
death. Brain Dev 32:275–284. https ://doi.org/10.1016/j.brain 
dev.2009.05.006
Li J, Chen S, Lin RCS, Smith SS (1997) Cerebellar nitric oxide syn-
thase is expressed within granule cell patches innervated by spe-
cific mossy fiber terminals: a developmental profile. Dev Neurosci 
19:274–282. https ://doi.org/10.1159/00011 1216
Luo L (2000) RHO GTPASES in neuronal morphogenesis. Nat Rev 
Neurosci 1:173–180. https ://doi.org/10.1038/35044 547
Luo L (2002) Actin cytoskeleton regulation in neuronal morphogenesis 
and structural plasticity. Annu Rev Cell Dev Biol 18:601–635
Manaker S, Tischler LJ, Bigler TL, Morrison AR (1992) Neurons of 
the motor trigeminal nucleus project to the hypoglossal nucleus 
in the rat. Exp Brain Res 90:262–270. https ://doi.org/10.1007/
BF002 27237 
Marchetti C, Pagnotta S, Donato R, Nistri A (2002) Inhibition of spi-
nal or hypoglossal motoneurons of the newborn rat by glycine 
or GABA. Eur J Neurosci 15:975–983. https ://doi.org/10.104
6/j.1460-9568.2002.01927 .x
Mize RR, Scheiner CA, Salvatore MF, Cork RJ (1997) Inhibition of 
nitric oxide synthase fails to disrupt the development of cholin-
ergic fiber patches in the rat superior colliculus. Dev Neurosci 
19:260–273. https ://doi.org/10.1159/00011 1215
Mody I, De Koninck Y, Otis TS, Soltesz I (1994) Bridging the cleft at 
GABA synapses in the brain. Trends Neurosci 17:517–525
Montero F, Portillo F, González-Forero D, Moreno-López B (2008) 
The nitric oxide/cyclic guanosine monophosphate pathway modu-
lates the inspiratory-related activity of hypoglossal motoneurons 
in the adult rat. Eur J Neurosci 28:107–116. https ://doi.org/10.11
11/j.1460-9568.2008.06312 .x
Montero F, Sunico CR, Liu B et al (2010) Transgenic neuronal nitric 
oxide synthase expression induces axotomy-like changes in adult 
motoneurons. J Physiol 588:3425–3443. https ://doi.org/10.1113/
jphys iol.2010.19539 6
Moreno-López B (2010) Local isoform-specific NOS inhibition: a 
promising approach to promote motor function recovery after 
nerve injury. J Neurosci Res 88:1846–1857
Moreno-López B, González-Forero D (2006) Nitric oxide and syn-
aptic dynamics in the adult brain: physiopathological aspects. 
Rev Neurosci 17:309–357. https ://doi.org/10.1515/REVNE 
URO.2006.17.3.309
Moreno-López B, Romero-Grimaldi C, Noval JA et al (2004) Nitric 
oxide is a physiological inhibitor of neurogenesis in the adult 
mouse subventricular zone and olfactory bulb. J Neurosci 24:85–
95. https ://doi.org/10.1523/JNEUR OSCI.1574-03.2004
Moreno-López B, Sunico CR, González-Forero D (2011) NO orches-
trates the loss of synaptic boutons from adult “sick” motoneurons: 
modeling a molecular mechanism. Mol Neurobiol 43:41–66. https 
://doi.org/10.1007/s1203 5-010-8159-8
Newey SE, Velamoor V, Govek EE, Van Aelst L (2005) Rho GTPases, 
dendritic structure, and mental retardation. J Neurobiol 64:58–74
Nikonenko I, Jourdain P, Muller D (2003) Presynaptic remodeling con-
tributes to activity-dependent synaptogenesis. J Neurosci 23:8498–
8505. https ://doi.org/10.1523/jneur osci.23-24-08498 .2003
O’Kusky JR (1998) Postnatal changes in the numerical density and 
total number of asymmetric and symmetric synapses in the hypo-
glossal nucleus of the rat. Dev Brain Res 108:179–191. https ://
doi.org/10.1016/S0165 -3806(98)00048 -0
O’Kusky JR, Norman MG (1995) Sudden infant death syndrome: 
increased number of synapses in the hypoglossal nucleus. J Neu-
ropathol Exp Neurol 54:627–634. https ://doi.org/10.1097/00005 
072-19950 9000-00003 
Ottaviani G, Matturri L, Mingrone R, Lavezzi AM (2006) Hypoplasia 
and neuronal immaturity of the hypoglossal nucleus in sudden 
infant death. J Clin Pathol 59:497–500. https ://doi.org/10.1136/
jcp.2005.03203 7
Paik SK, Il Yoo H, Choi SK et al (2019) Distribution of excitatory and 
inhibitory axon terminals on the rat hypoglossal motoneurons. 
Brain Struct Funct 224:1767–1779. https ://doi.org/10.1007/s0042 
9-019-01874 -0
Remmers JE, DeGroot WJ, Sauerland EK, Anch AM (1978) Pathogen-
esis of upper airway occlusion during sleep. J Appl Physiol Respir 
Environ Exerc Physiol 44:931–938. https ://doi.org/10.1152/jappl 
.1978.44.6.931
Roskams AJ, Bredt DS, Dawson TM, Ronnett GV (1994) Nitric oxide 
mediates the formation of synaptic connections in developing and 
regenerating olfactory receptor neurons. Neuron 13:289–299. 
https ://doi.org/10.1016/0896-6273(94)90347 -6
Samama B, Boehm N (1996) Ontogenesis of NADPH-diaphorase 
activity in the olfactory bulb of the rat. Dev Brain Res 96:192–
203. https ://doi.org/10.1016/0165-3806(96)00120 -4
Stevens B, Allen NJ, Vazquez LE et al (2007) The classical comple-
ment cascade mediates CNS synapse elimination. Cell 131:1164–
1178. https ://doi.org/10.1016/j.cell.2007.10.036
Sunico CR, Portillo F, González-Forero D, Moreno-López B (2005) 
Nitric oxide-directed synaptic remodeling in the adult mammal 
CNS. J Neurosci 25:1448–1458. https ://doi.org/10.1523/JNEUR 
OSCI.4600-04.2005
Sunico CR, González-Forero D, Domínguez G et al (2010) Nitric oxide 
induces pathological synapse loss by a protein kinase G-, Rho 
kinase-dependent mechanism preceded by myosin light chain 
phosphorylation. J Neurosci 30:973–984. https ://doi.org/10.1523/
JNEUR OSCI.3911-09.2010
Sunico CR, Domínguez G, García-Verdugo JM et al (2011) Reduction 
in the motoneuron inhibitory/excitatory synaptic ratio in an early-
symptomatic mouse model of amyotrophic lateral sclerosis. Brain 
Pathol 21:1–15. https ://doi.org/10.1111/j.1750-3639.2010.00417 
.x
Takada M, Itoh K, Yasui Y et al (1984) Distribution of premotor neu-
rons for the hypoglossal nucleus in the cat. Neurosci Lett 52:141–
146. https ://doi.org/10.1016/0304-3940(84)90364 -1
Talley EM, Lei Q, Sirois JE, Bayliss DA (2000) TASK-1, a two-pore 
domain K + channel, is modulated by multiple neurotransmitters 
in motoneurons. Neuron 25:399–410
Travers JB, Norgren R (1983) Afferent projections to the oral motor 
nuclei in the rat. J Comp Neurol 220:280–298. https ://doi.
org/10.1002/cne.90220 0303
Ugolini G, Kuypers HGJM, Simmons A (1987) Retrograde transneu-
ronal transfer of Herpes simplex virus type 1 (HSV 1) from moto-
neurones. Brain Res 422:242–256. https ://doi.org/10.1016/0006-
8993(87)90931 -0
Vazquez C, Anesetti G, Martinez Palma L (1999) Transient expression 
of nitric oxide synthase in the hypoglossal nucleus of the rat dur-
ing early postnatal development. Neurosci Lett 275:5–8. https ://
doi.org/10.1016/S0304 -3940(99)00686 -2
Vercelli A, Repici M, Biasiol S, Jhaveri S (1999) Maturation of 
NADPH-d activity in the rat’s barrel-field cortex and its relation-
ship to cytochrome oxidase activity. Exp Neurol 156:294–315. 
https ://doi.org/10.1006/exnr.1999.7025
Williams CV, Nordquist D, McLoon SC (1994) Correlation of nitric 
oxide synthase expression with changing patterns of axonal pro-
jections in the developing visual system. J Neurosci 14:1746–
1755. https ://doi.org/10.1523/jneur osci.14-03-01746 .1994
2884 Brain Structure and Function (2020) 225:2871–2884
1 3
Williams PA, Bellinger DL, Wilson CG (2019a) Changes in the 
morphology of hypoglossal motor neurons in the brainstem of 
developing rats. Anat Rec 302:869–892. https ://doi.org/10.1002/
ar.23971 
Williams PA, Dalton C, Wilson CG (2019b) Modeling hypoglossal 
motoneurons in the developing rat. Respir Physiol Neurobiol 
265:40–48. https ://doi.org/10.1016/j.resp.2018.07.009
Wu HH, Williams CV, McLoon SC (1994) Involvement of nitric 
oxide in the elimination of a transient retinotectal projection 
in development. Science (80-) 265:1593–1596. https ://doi.
org/10.1126/scien ce.75215 41
Yamagata M, Sanes JR, Weiner JA (2003) Synaptic adhesion mol-
ecules. Curr Opin Cell Biol 15:621–632
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
